Webinars, Videos and Articles


This webinar demonstrates the pharmacist-centric education and customizable multi-media marketing resources available to Pharmacy owners and their staff on the NCPACBDSource.com website. Tim Gregorius, VP of Operations, Evan Gregorius, Marketing Assistant and Linda Barnes, Director of Marketing review the live version of the site showcasing its features while touching on important aspects of the Endocannabinoid System, new technology pertaining to CBD and everything a pharmacist would need to successfully sell CBD in their Pharmacy.

June 25, 2020 – Morning Session

June 24, 2020 – Evening Session


Tim Gregorius, VP of Operations, and Evan Gregorius, Marketing Assistant discuss a wide range of topics pertaining to CBD including the importance of the Endocannabinoid System (ECS), legal issues, marketing CBD to your customers, pertinent information regarding dosing and drug interactions,  and new innovations that are increasng the bioavailability of CBD.

March 12, 2020 – Session #1

March 12, 2020 – Session #2


Tim Gregorius, VP of Operations, and Evan Gregorius, Marketing Assistant discuss CBD in detail including why you need to understand CBD and the Endocannabinoid System (ECS), and how to effectively market CBD to your customers, who may already be buying CBD from a gas station or corner store. Also, an introduction to the NCPA CBD Source website and its purpose.

December 12, 2019 – Session #1

December 12, 2019 – Session #2

CBD For Pharmacy: The Endocannabinoid System (ECS)

Tim Gregorius, VP of Operations, and guest Evan Gregorius educate attendees on the Endocannabinoid System (ECS) and its relationship to CBD as well as answer questions pertaining to the ECS and CBD in general.

August 8, 2019 – Session #1

August 8, 2019 – Session #2

Everything you want to know
about selling CBD in your pharmacy

Tim Gregorius, VP of Operations, educate attendees on CBD and relays important information as well as answer questions related to selling CBD products in the independent pharmacy setting.

June 13, 2019 – Session #1

June 13, 2019 – Session #2

NCPA CBD Source, Powered By PRS

Journal Articles Regarding CBD and the ECS

Endocannabinoid System Functions

The endocannabinoid system: An emotional buffer in the modulation of memory function

The endocannabinoid system and associative learning and memory in zebrafish. – PubMed – NCBI

The endocannabinoid system: An emotional buffer in the modulation of memory function – ScienceDirect

Cell-autonomous excitation of midbrain dopamine neurons by endocannabinoid-dependent lipid signaling

Multiple Mechanistically Distinct Modes of Endocannabinoid Mobilization at Central Amygdala Glutamatergic Synapses

Exploring The Molecular Basis Of “Runner’s High” | Chemical & Engineering News

Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far

Control of synaptic function by endocannabinoid-mediated retrograde signaling.

Activity-Dependent Regulation of Synapses by Retrograde Messengers

Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease

Cannabinoid CB1 and CB2 Receptor Signaling and Bias

About Cannabinoid Signalling

CB1 circuit function

Retrograde Inhibition of Presynaptic Calcium Influx by Endogenous Cannabinoids at Excitatory Synapses onto Purkinje Cells: Neuron

Polymodal activation of the endocannabinoid system in the extended amygdala | Nature Neuroscience

ECS dopamine regulation

The endocannabinoid system and liver diseases. – PubMed – NCBI

The endocannabinoid system: an emotional buffer in the modulation of memory function.

Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration

The role of the endocannabinoid system in pain. – PubMed – NCBI

The Endocannabinoid System, Cannabinoids, and Pain

The cannabinoid system and pain – ScienceDirect

The endocannabinoid system and neuropathic pain : PAIN

Feeling Pain and Being in Pain

Cannabinoids in the management of difficult to treat pain

Cannabinoids in the management of difficult to treat pain (1)

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

Suppression of Noxious Stimulus-Evoked Activity in the Ventral Posterolateral Nucleus of the Thalamus by a Cannabinoid Agonist: Correlation between Electrophysiological and Antinociceptive Effects | Journal of Neuroscience

Terpenes and Lipids of the Endocannabinoid and Transient-Receptor-Potential-Channel Biosignaling Systems

Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System | Science

Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey

Interactions between ethanol and the endocannabinoid system at GABAergic synapses on basolateral amygdala principal neurons

Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: A critical review of preclinical research

A biophysical model of endocannabinoid-mediated short term depression of excitation in hippocampus

New insights into the yin and yang of the endocannabinoid system in health and disease

The endocannabinoid system in renal cells: regulation of Na+ transport by CB1 receptors through distinct cell signalling pathways

The endocannabinoid system regulates synaptic transmission in nucleus accumbens by increasing DAGL‐α expression following short‐term morphine withdrawal

Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism | Nature Neuroscience

The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease

The endocannabinoid system: an overview

Contribution of Endocannabinoid Gene Expression and Genotype… : The Clinical Journal of Pain

Components of the cannabinoid system in the dorsal periaqueductal gray are related to resting heart rate

The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities

The Endocannabinoid System and Its Role in Regulating the Intrinsic Neural Circuitry of the Gastrointestinal Tract – ScienceDirect

Multiple Functions of Endocannabinoid Signaling in the Brain

Endocannabinoid signaling and synaptic function

Multiple Forms of Endocannabinoid and Endovanilloid Signaling Regulate the Tonic Control of GABA Release

The Endocannabinoid System and its Modulation by Phytocannabinoids

The Endocannabinoid System and Pain

An introduction to the endogenous cannabinoid system

Dynamic regulation of the endocannabinoid system: implications for analgesia

Supply and demand for endocannabinoids

Tonic Modulation of Spinal Hyperexcitability by the Endocannabinoid Receptor System in a Rat Model of Osteoarthritis Pain

The evolution and comparative neurobiology of endocannabinoid signalling

Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: a longitudinal study in multiple sclerosis patients

Activation of Endocannabinoid System Is Associated with Persistent Inflammation in Human Aortic Aneurysm

Expression of the endocannabinoid system in fibroblasts and myofascial tissues – Journal of Bodywork and Movement Therapies

Pre‐synaptic adenosine A2A receptors control cannabinoid CB1 receptor‐mediated inhibition of striatal glutamatergic neurotransmission – Martire – 2011 – Journal of Neurochemistry – Wiley Online Library

Endocannabinoid-Mediated Control of Synaptic Transmission | Physiological Reviews

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 | Pharmacological Reviews

Cannabinoid activation of PPARα; a novel neuroprotective mechanism

An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors

The putative cannabinoid receptor GPR55 plays a role in mech… : PAIN

The orphan receptor GPR55 is a novel cannabinoid receptor

The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo

The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. – PubMed – NCBI

Modulation of l-α-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids

Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling

Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation

Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype

Stress Regulates Endocannabinoid-CB1 Receptor Signaling

The multiple waves of cannabinoid 1 receptor signaling

Cannabinoid Receptors: Where They are and What They do

Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain

Cannabinoid receptor type-1: breaking the dogmas – F1000Research

Altered surface trafficking of presynaptic cannabinoid type 1 receptor in and out synaptic terminals parallels receptor desensitization | PNAS

Localization of CB1 in Rat Brain

Endocannabinoid System Receptors and Enzymes

The pharmacology of cannabinoid receptors and their ligands: an overview. – PubMed – NCBI

Emerging strategies for exploiting cannabinoid receptor agonists as medicines – Pertwee – 2009 – British Journal of Pharmacology – Wiley Online Library

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin

CB1 vs. CB2

Differential Roles of CB1 and CB2 Cannabinoid Receptors in Mast Cells

Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor | Journal of Pharmacology and Experimental Therapeutics

2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons. – PubMed – NCBI

Assessing Allosteric Modulation of CB1 at the Receptor and Cellular Levels

Crystal structure of CB1

Circuit Specific Functions of Cannabinoid CB1 Receptor in the Balance of Investigatory Drive and Exploration

CB Receptor | Cannabinoid receptors | IUPHAR/BPS Guide to PHARMACOLOGY

(−)-β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis

Cannabinoid receptor 2: Potential role in immunomodulation and neuroinflammation Review

Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target

About CB2

What We Know and Don’t Know About the Cannabinoid Receptor 2 (CB2)

Mechanism of CB2

CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold?

Agonist-Directed Trafficking of Response by Endocannabinoids Acting at CB2 Receptors | Journal of Pharmacology and Experimental Therapeutics

Chronic activation of CB2 cannabinoid receptors in the hippocampus increases excitatory synaptic transmission

The CB2 receptor and its role as a regulator of inflammation

Experimental Cannabinoid 2 Receptor-Mediated Immune Modulation in Sepsis

Endocannabinoid Signaling Molecules

Endocannabinoids | SpringerLink

Conversation with Raphael Mechoulam – – 2007 – Addiction – Wiley Online Library

Dual mechanism of TRKB activation by anandamide through CB1 and TRPV1 receptors

Upregulation of Anandamide Hydrolysis in the Basolateral Complex of Amygdala Reduces Fear Memory Expression and Indices of Stress and Anxiety

Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years

Protective Action of Anandamide and Its COX-2 Metabolite against l-Homocysteine-Induced NLRP3 Inflammasome Activation and Injury in Podocytes

Deficient Adolescent Social Behavior Following Early-Life Inflammation is Ameliorated by Augmentation of Anandamide Signaling

Anti-carcinogenic activity of anandamide on human glioma in vitro and in vivo

The Effects of the Endocannabinoids Anandamide and 2-Arachidonoylglycerol on Human Osteoblast Proliferation and Differentiation

Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation

Anandamide inhibits breast tumor-induced angiogenesis

The neuroprotective mechanism of 2-arachidonoylglycerol 2-AG against non-caspase-dependent apoptosis in mice hippocampal neurons following MCAO

The Ratio of 2-AG to Its Isomer 1-AG as an Intrinsic Fine Tuning Mechanism of CB1 Receptor Activation

Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

Chemical Approaches to Therapeutically Target the Metabolism and Signaling of the Endocannabinoid 2-AG and Eicosanoids

The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG

The Major Brain Endocannabinoid 2-AG Controls Neuropathic Pain and Mechanical Hyperalgesia in Patients with Neuromyelitis Optica

Modulation of the Endocannabinoids N-Arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on Executive Functions in Humans

Frequency-Dependent Cannabinoid Receptor-Independent Modulation of Glycine Receptors by Endocannabinoid 2-AG

Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain

A model of endocannabinoid 2-AG-mediated depolarization-induced suppression of inhibition

Subcellular Arrangement of Molecules for 2-Arachidonoyl-Glycerol-Mediated Retrograde Signaling and Its Physiological Contribution to Synaptic Modulation in the Striatum

2-Arachidonoylglycerol (2-AG) membrane transport: History and outlook

Localization of Diacylglycerol Lipase-α around Postsynaptic Spine Suggests Close Proximity between Production Site of an Endocannabinoid, 2-Arachidonoyl-glycerol, and Presynaptic Cannabinoid CB1 Receptor

Prefrontal Cortex Stimulation Induces 2-Arachidonoyl-Glycerol-Mediated Suppression of Excitation in Dopamine Neurons

Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor-dependent G-protein activation in rat cerebellar membranes

2-AG full agonist; antag. by AEA

The Ratio of 2-AG to Its Isomer 1-AG as an Intrinsic Fine Tuning Mechanism of CB1 Receptor Activation


N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1

N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities

Identification of N‐arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors

A Cannabinoid Receptor Agonist N-Arachidonoyl Dopamine Inhibits Adipocyte Differentiation in Human Mesenchymal Stem Cells

The Endocannabinoid/Endovanilloid N-Arachidonoyl Dopamine (NADA) and Synthetic Cannabinoid WIN55,212-2 Abate the Inflammatory Activation of Human Endothelial Cells

Uncoupling of sarcoplasmic reticulum Ca2+-ATPase by N-arachidonoyl dopamine. Members of the endocannabinoid family as thermogenic drugs

Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays

The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine

Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine

Microsomal omega-hydroxylated metabolites of N-arachidonoyl dopamine are active at recombinant human TRPV1 receptors

Modulation of trigeminal sensory neuron activity by the dual cannabinoid–vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide

Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA)

An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors

N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities

N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo

CBD Interaction With Physiological and Pathological Conditions

TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer. – PubMed – NCBI

Cannabinoids – a new weapon against cancer?

The influence of biomechanical properties and cannabinoids on tumor invasion. – PubMed – NCBI

The inhibitory effects of cannabidiol on systemic malignant tumors. – PubMed – NCBI

Cannabidiol inhibits angiogenesis by multiple mechanisms. – PubMed – NCBI

Cannabidiol as potential anticancer drug

Cannabis and Cannabinoids (PDQ®)—Health Professional Version – National Cancer Institute

Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells

Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy

Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies. – PubMed – NCBI

Cannabinoid receptors and the regulation of bone mass

[The endocannabinoid system and bone]. – PubMed – NCBI

Role of cannabinoids in the regulation of bone remodeling

The Pathophysiology and Treatment of Osteoporosis. – PubMed – NCBI

Migraines and headaches – does CBD help?

5 Facts About CBD Oil For Migraine Headaches – FibroToday.com

Parkinson’s Disease – Medical Marijuana Research Overview

CBD and motor neuron disease

A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinso… – PubMed – NCBI

Cannabinoids in Parkinson’s Disease

The endocannabinoid system in amyotrophic lateral sclerosis. – PubMed – NCBI

Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?

The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. – PubMed – NCBI

Huntington disease: a single-gene degenerative disorder of the striatum

RCSB PDB – 6EZ8: Human Huntingtin-HAP40 complex structure

HTT gene – Genetics Home Reference

Endocannabinoid signaling in microglial cells

Cannabinoid and cannabinoid-like receptors in microglia, astrocytes and astrocytomas

Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation | Journal of Neuroinflammation | Full Text

Multiple sclerosis – ScienceDirect

Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis | Brain | Oxford Academic

Monoclonal Antibody Treatment Exposes Three Mechanisms Underlying the Clinical Course of Multiple Sclerosis

Multiple sclerosis: Lessons from molecular neuropathology – ScienceDirect

Scopus preview – Scopus – Document details

Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis: Trends in Molecular Medicine

The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases

Lennox-Gastaut syndrome: a comprehensive review | SpringerLink

Lennox-Gastaut syndrome

Treatment of Lennox-Gastaut syndrome: overview and recent findings

Lennox-Gastaut Syndrome – NORD (National Organization for Rare Disorders)

Lennox-Gastaut Syndrome (LGS) | Epilepsy Foundation

Lennox-Gastaut Syndrome: Causes, Symptoms, and Treatment

Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4) (S21.001) | Neurology

Lennox-Gastaut Syndrome: Cannabidiol Treatment | Neurology Times

Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy

Drop Seizure Frequency in Lennox-Gastaut Decreased With Cannabidiol

Images in Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial – The Lancet Neurology

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome | NEJM

Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. – PubMed – NCBI

Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4) (S21.001)

Non-Pharmacological Therapies for LGS

Drop Seizure Frequency in Lennox-Gastaut Decreased With Cannabidiol

GW Pharmaceuticals and Its U.S. Subsidiary Greenwich Biosciences Completes Rolling New Drug Application Submission to U.S. Food and Drug Administration for Epidiolex® (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome | GW Phar

The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages

Deficient Adolescent Social Behavior Following Early-Life Inflammation is Ameliorated by Augmentation of Anandamide Signaling

Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive beh

AUTISM RESEARCH Stock Video, Footage – AUTISM RESEARCH HD Video Clips | Bigstock

Autism-Associated Neuroligin-3 Mutations Commonly Impair Striatal Circuits to Boost Repetitive Behaviors

Cannabis Spray Treatment Helps 9-Year-Old with Autism Learn to Speak | Parenting

Endocannabinod Signal Dysregulation in Autism Spectrum Disorders: A Correlation Link between Inflammatory State and Neuro-Immune Alterations

Alterations of GABAergic Signaling in Autism Spectrum Disorders

Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage

Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy

Comparison of Cannabidiol, Antioxidants, and Diuretics in Reversing Binge Ethanol-Induced Neurotoxicity

Cannabis Use in Patients with Fibromyalgia: Effect on Symptoms Relief and Health-Related Quality of Life

CBD relieves the symptoms of ALS

Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?

The Physiology of Fear: Reconceptualizing the Role of the Central Amygdala in Fear Learning

Cannabidiol Modulates Fear Memory Formation Through Interactions with Serotonergic Transmission in the Mesolimbic System

Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life

Towards a mechanistic understanding of pathological anxiety: the dorsal medial prefrontal-amygdala ‘aversive amplification’ circuit in unmedicated generalized and social anxiety disorders

Cannabidiol as a Potential Treatment for Anxiety Disorders

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

Endocannabinoid signaling in social functioning: an RDoC perspective

Drug effects on responses to emotional facial expressions: recent findings

Cannabidiol Regulation of Learned Fear: Implications for Treating Anxiety-Related Disorders

Does Rejection Hurt? An fMRI Study of Social Exclusion

Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report

5-HT1A Receptor: The “Single” and “Self-Transcendent” Receptor – Selfhacked

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug

Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?

5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats

Cannabidiol, or CBD, Benefits for Pain, Mental Illness & Anxiety – Dr. Axe

Evidences for the Anti-panic Actions of Cannabidiol

Cannabinoids for gastrointestinal diseases: potential therapeutic applications

Crohn’s disease – Symptoms and causes – Mayo Clinic

Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis

Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?

Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028—study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation

HIV-infected cannabis users have lower circulating CD16+ monocytes and IP-10 levels compared to non-using HIV patients

Δ9-Tetrahydrocannabinold (THC) suppresses secretion of IFNα by plasmacytoid dendritic cells (pDC) from healthy and HIV-infected individuals

Cannabinoid inhibits HIV-1 Tat-stimulated adhesion of human monocyte-like cells to extracellular matrix proteins

Marijuana Use and Viral Suppression in Persons Receiving Medical Care for HIV-Infection

Neighborhood-level and individual-level correlates of cannabis use among young persons living with HIV/AIDS

Behavioral, metabolic, and immune consequences of chronic alcohol or cannabinoids on HIV/AIDs: Studies in the Non-Human Primate SIV model

Behavioral, metabolic, and immune consequences of chronic alcohol or cannabinoids on HIV/AIDs: Studies in the Non-Human Primate SIV model

CB2 Receptor Agonists Protect Human Dopaminergic Neurons against Damage from HIV-1 gp120

Marijuana Smoking Does Not Accelerate Progression of Liver Disease in HIV–Hepatitis C Coinfection: A Longitudinal Cohort Analysis

Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial

How does HIV cause depletion of CD4 lymphocytes? A mechanism involving virus signaling through its cellular receptors. – PubMed – NCBI

Making sense of how HIV kills infected CD4 T cells: implications for HIV cure

Cannabinoids as novel anti-inflammatory drugs

Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption

The Profile of Immune Modulation by Cannabidiol (CBD) Involves Deregulation of Nuclear Factor of Activated T Cells (NFAT)

Adrenal Insufficiency Syndrome

Addison Disease – Endocrine and Metabolic Disorders – Merck Manuals Professional Edition

Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. – PubMed – NCBI

Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice

Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes

CBD Literature Available in Spanish

Is Cannabidiol an Effective Treatment for Schizophrenia? // ¿Es el cannabidiol un tratamiento eficaz para la esquizofrenia?

Cannabidiol: Its Use in Refractory Epilepsies // Cannabidiol: su uso en epilepsias refractarias

Delta-9-tetrahydrocannabinol-cannabidiol in the Treatment of Spasticity in Chronic Spinal Cord Injury: A Clinical Experience // Delta-9-tetrahidrocannabinol-cannabidiol en el tratamiento de la espasticidad en la lesión crónica de la médula espinal: una experiencia clínica

New Antiepileptic Drugs // Nuevas Drogas Antiepilépticas

New Anti-Epileptic Drugs in Paediatrics // Nuevos medicamentos antiepilépticos en pediatría

Compassionate Use of Cannabidiol in Spray Form for the Treatment of Spastic Paraparesis in a Patient With Adrenomyeloneuropathy // Uso compasivo de cannabidiol en forma de aerosol para el tratamiento de la paraparesia espástica en un paciente con adrenomieloneuropatía

Psychoactive Constituents of Cannabis and Their Clinical Implications: A Systematic Review // Constituyentes psicoactivos del cannabis y sus implicaciones clínicas: una revisión sistemática

Treatment of Spasticity in Multiple Sclerosis: New Perspectives Regarding the Use of Cannabinoids // Tratamiento de la espasticidad en la esclerosis múltiple: nuevas perspectivas sobre el uso de cannabinoides

Cannabinoids in Epilepsy: Clinical Efficacy and Pharmacological Considerations // Cannabinoides en la epilepsia: eficacia clínica y consideraciones farmacológicas

Clinical Experiences With Cannabinoids in Spasticity Management in Multiple Sclerosis // Experiencias clínicas con cannabinoides en el manejo de la espasticidad en la esclerosis múltiple

Assessment of the Effectiveness and Safety of Sativex® in Compassionate Use // Evaluación de la efectividad y seguridad de Sativex® en uso compasivo

Cannabis Use in Epilepsy. Current Situation in Argentina and Abroad // Uso de cannabis en la epilepsia. Situación actual en Argentina y en el extranjero

The Treatment of Cannabis Dependence: Clinical Work, Psychotherapy and Evidence // El tratamiento de la dependencia del cannabis: trabajo clínico, psicoterapia y evidencia

Sign up today for our NEW webinar!

CBD in Pharmacy: 2020 takes you beyond the typical “WHAT IS CBD” and dives deep into the real information you need to know to correctly counsel and successfully sell CBD to your customers.

We will cover…

CBD Legal Issues with up to date information on specific state laws, the FDA, the DEA, what you are allowed to say in advertising and more!

Marketing CBD with tips on how to market CBD to your local doctors and customers so you can successfully brand yourself as the community CBD Expert!

Endocannabinoid System…we take an in-depth look at this complex system and discuss how to use the ECS to talk to your patients about CBD.

We will outline the “do’s and don’ts” of CBD Dosing information and guidelines.

Learn about NEW Innovations that increase the bioavailablility of CBD! We will cover nano-technology, liposomal delivery and MORE!

Listen to our CBD experts discuss Drug Interactions and what you need to know to correctly counsel your customers on whether they SHOULD take CBD.

Plus time for questions and answers so you can be part of the discussion and get YOUR questions about CBD answered!